Login to Your Account



BMS gets much-needed I-O boost on Opdivo OS data

By Marie Powers
News Editor

Monday, April 3, 2017

Bristol-Myers Squibb Co. fell back in the I-O pack last year after reporting that its blockbuster, Opdivo, failed to achieve statistically significant PFS in the phase III CHECKMATE-026 trial. But the company showed at the AACR meeting that it's still in the I-O race.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription